Clinical Vignette
Patient: "Mr. Z," 29-year-old unemployed welder, brought to ED by police after neighbors reported him screaming about 'shadow people' and breaking windows in his apartment.
Chief Concern: Police: "Subject was observed yelling at empty corners, stated 'shadow people' were coming through the walls, and broke 3 windows. He was agitated and physically combative. Found methamphetamine paraphernalia in the apartment."
History of Present Illness: Mr. Z has been using methamphetamine for 4 years, with escalation over the past 18 months. His current use pattern involves 'binge-crash' cycling: 4-5 day continuous use binges (staying awake the entire period, smoking methamphetamine every 2-3 hours), followed by 2-3 day 'crash' periods of hypersomnia and depression. During his current binge (day 4, no sleep for approximately 96 hours), he developed paranoid delusions (neighbors spying on him, 'shadow people' entering his apartment) and visual hallucinations (shadow figures in peripheral vision). He has experienced methamphetamine-induced psychotic symptoms during 3 previous binges, each resolving within 24-48 hours of sleep and cessation. He consumes 2-3 grams per day during binges. Consequences: lost welding job (absenteeism), evicted twice, 30-pound weight loss over 18 months, dental damage ('meth mouth' with missing upper teeth), arrested twice for possession. He reports craving as 'the most intense urge I've ever felt' and describes escalating doses for effect (tolerance).
Medical History: Dental caries and tooth loss. 30-pound weight loss. Tachycardia. Skin excoriations (picking during intoxication).
Mental Status Exam: Agitated, diaphoretic, scanning room. HR 128, BP 178/102. Pupils dilated. Dentition poor (missing teeth, caries). Multiple skin excoriations on arms and face. Speech rapid, tangential. Paranoid: 'shadow people' delusions. Visual hallucinations (peripheral shadows). Oriented but distractible. No insight during acute episode.
Step 1: Stimulant Use Disorder DSM-5-TR Criteria
Summary of criteria met:
(1) Larger amounts (dose escalation). (2) Unsuccessful efforts to stop (3 failed attempts). (3) Great deal of time obtaining/using/recovering. (4) Craving ('most intense urge'). (5) Failure to fulfill obligations (lost job). (6) Continued despite social problems (evictions, arrests). (7) Activities given up. (8) Physically hazardous (driving while intoxicated on meth). (9) Continued despite knowledge of problems (weight loss, dental damage, psychotic episodes). (10) Tolerance (dose escalation for same effect). (11) Withdrawal (crash period: hypersomnia, depression). Total: 11/11. SEVERITY: SEVERE. 11/11 CRITERIA MET. SEVERE.
Step 2: Methamphetamine-Induced Psychosis
| Feature | Meth-Induced Psychosis | Primary Schizophrenia | This Patient |
|---|---|---|---|
| Temporal relationship | Emerges during binge (especially after sleep deprivation) | No substance relationship | Day 4 of binge, 96 hours no sleep |
| Hallucination type | Visual > auditory; 'shadow people' classic | Auditory > visual | Visual: shadow people — classic meth pattern |
| Resolution | Resolves with sleep and cessation (24-48 hours) | Persistent | Prior episodes resolved in 24-48 hours |
| Skin picking | Common (formication — 'bugs under skin') | Uncommon | Present: multiple excoriations |
| Paranoia content | Surveillance, shadow figures | Variable | Neighbors spying, shadow people |
Medical Emergency Management
Mr. Z presents with stimulant-induced psychosis AND medical emergency: HR 128, BP 178/102 (hypertensive emergency risk for stroke or aortic dissection). Immediate priorities: cardiovascular monitoring, benzodiazepine for agitation (NOT haloperidol — which lowers seizure threshold), IV hydration, and observation for resolution of psychosis with sleep.
Diagnostic Formulation
Diagnostic Conclusion
Stimulant Use Disorder (Methamphetamine Type), Severe (F15.20) + Stimulant-Induced Psychotic Disorder (F15.259): All 11 DSM-5-TR criteria for SUD met. Concurrent stimulant-induced psychosis (paranoid delusions, visual hallucinations). Treatment acute: benzodiazepine (NOT antipsychotics first-line due to seizure threshold), cardiovascular monitoring, IV fluids, facilitate sleep. Treatment post-acute: no FDA-approved medication for stimulant use disorder. Psychosocial: contingency management (strongest evidence), CBT, Matrix Model (structured outpatient). Address dental, nutritional, and housing needs.
Teaching Points
- There are currently NO FDA-approved medications for stimulant use disorder. This contrasts with opioid and alcohol use disorders, which have pharmacological treatments. Research is ongoing with bupropion, naltrexone, and mirtazapine combinations, but no definitive pharmacotherapy exists.
- Contingency management (providing tangible incentives for stimulant-free urine tests) has the strongest evidence base for stimulant use disorders. It leverages the dopaminergic reward system that stimulants dysregulate.
- Methamphetamine-induced psychosis characteristically features visual hallucinations (especially 'shadow people' — peripheral shadow figures) and paranoid delusions (surveillance, persecution). This pattern differs from primary schizophrenia, which predominantly features auditory hallucinations. Sleep deprivation during binges is a major contributing factor.
- Cardiovascular complications of methamphetamine include: hypertension, tachycardia, arrhythmia, cardiomyopathy, aortic dissection, and hemorrhagic stroke. Mr. Z's BP 178/102 and HR 128 require immediate management. Methamphetamine is directly cardiotoxic.
- Benzodiazepines are preferred over antipsychotics for acute stimulant-induced agitation. Traditional antipsychotics (especially haloperidol) lower the seizure threshold, which is already reduced by stimulant intoxication. Benzodiazepines address agitation, reduce sympathomimetic toxicity, and do not increase seizure risk.